The Plasma segment focuses on providing automated plasma collection devices, related disposables, and software solutions. Research and development efforts concentrate on enhancing the efficiency and safety of plasmapheresis procedures. Technologies include automated plasma collection systems like NexSys PCS and PCS2, along with integrated information technology platforms for managing donors, operations, and the supply chain. This segment addresses the need for high-quality plasma for various therapeutic applications, impacting patient outcomes by ensuring a reliable supply of plasma-derived products. Haemonetics maintains a strong market position by continuously innovating and improving its plasma collection technologies. Future opportunities include expanding into new markets and developing advanced plasma collection methods. Regulatory compliance and clinical validation are critical aspects of this segment, ensuring the safety and efficacy of the products. Partnerships with plasma centers and blood banks are essential for market access and distribution.

The Blood Center segment offers automated blood component and manual whole blood collection systems. Research and development activities are focused on improving the efficiency and safety of blood collection and processing. Key technologies include MCS brand apheresis equipment, disposable whole blood collection and component storage sets, and software solutions like SafeTrace Tx and El-Dorado Donor. This segment supports blood banks and transfusion services, ensuring a safe and reliable blood supply for patients. Haemonetics' products are designed to enhance donor recruitment and retention, improve blood unit management, and streamline blood drive planning. The company's market position is strengthened by its comprehensive product portfolio and commitment to innovation. Future growth opportunities include expanding into emerging markets and developing advanced blood processing technologies. Regulatory compliance and clinical validation are crucial for ensuring the safety and efficacy of blood products. Partnerships with blood centers and hospitals are essential for market access and distribution.

The Hospital segment provides products for use in the surgical suite and hospital transfusion service spaces. Research and development efforts are focused on improving patient outcomes through advanced diagnostic and blood management solutions. Key technologies include TEG diagnostic systems for assessing coagulation status, Cell Saver Elite+ for autologous blood recovery, and BloodTrack, a suite of blood management and bedside transfusion solutions. This segment addresses critical needs in surgery and critical care, impacting patient outcomes by improving blood management and reducing the need for transfusions. Haemonetics' market position is enhanced by its innovative product offerings and focus on improving patient safety. Future opportunities include expanding the product portfolio and developing advanced point-of-care diagnostic tools. Regulatory compliance and clinical validation are essential for ensuring the safety and efficacy of hospital products. Partnerships with hospitals and healthcare providers are crucial for market access and product adoption.